INTRODUCTION
Diabetes is associated with a unique cardiomyopathy that is independent of vascular disease and that contributes to a greater propensity for heart failure and arrhythmias in diabetics than the general population (32,40). The onset of clinical diabetic cardiomyopathy is marked by a slowing in relaxation kinetics and diastolic dysfunction, but as the syndrome progresses systolic dysfunction emerges, exacerbating the overall decline in ventricular performance (14) . The depressed contractile features of the diabetic heart are proposed to be due to perturbations in Ca 2+ handling, actin-myosin interactions or a combination of both (32, 40) . While changes in expression of Ca 2+ handling and myofilament proteins have been shown in experimental models of diabetic cardiomyopathy, it is also well recognized that post-translational modification of these proteins can significantly affect contractile performance in the absence of or in addition to changes in expression. One type of protein modification that may play a central role is the reversible oxidation of amino acid side chains, particularly those of cysteine and methionine residues (9, 10, 36, 38) . These residues are susceptible to modification by a variety of reactive oxygen species and their by-products.
Clinical and experimental studies suggest that ventricular dysfunction associated with diabetes mellitus is linked to a multitude of metabolic disturbances that results in increased production of reactive oxygen species and pathophysiological changes in myocyte function (8, 12) . In mammalian cells, the reduced form of the 4 (11, 46, 50, 51) . Most notably, GSH depletion and increased content of oxidized cellular proteins have been shown to play important roles in the pathogenesis of chronic diabetes (8, 11, 50) . Many of the pathogenic changes elicited in early stages of diabetes can be reversed or prevented by manipulating endogenous pathways affecting intracellular [GSH] , indicating that GSH is essential to cell viability and normal cell function (50) .
It has recently been proposed that pathways of glucose metabolism are involved in the control of myocardial GSH (1, 31, 35, 42, 50) . In the case of diabetes, the well documented decrease in myocardial insulin signaling and glucose utilization (19, 34) are likely factors contributing to alterations in GSH status.
Accordingly, insulin replacement therapy in type 1 diabetic models maintains normal cardiac GSH levels (31, 43, 51) . Recent data from our laboratory also provide functional evidence for a link between glucose metabolism and cell GSH. For example, up-regulation of voltage-gated K + channels in diabetic rat ventricular myocytes by insulin is blocked by inhibitors of GSH metabolism and is mimicked by exogenous GSH (50) .
These and related studies (35) support the notion that an important effect of insulin signaling pathways on cardiac function is the regulation of [GSH] and the control of cell redox state.
The present study examined mechanisms of GSH regulation in the setting of diabetic cardiomyopathy. Our data suggest that GSH depletion in the diabetic heart involves loss of function of major GSH enzymes and decreased substrate availability for glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting step of the pentose pathway. This shift in GSH status is associated with depressed myocyte mechanical function and Ca handling are also normalized by exogenous GSH or N-acetylcysteine. These results support the hypothesis that an essential function of glucose metabolism in the heart is the supply of NADPH via the pentose pathway to maintain adequate GSH levels for the redox control of intracellular Ca 2+ handling and contraction. Blood glucose levels were measured 3 days after STZ injection to confirm hyperglycemia. Normal rats of similar age and weight injected with vehicle only (1 mmol/l citrate buffer, pH 4.5) were used as controls.
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MATERIALS and METHODS
Induction of diabetes and isolation of myocytes
Diabetic rats at the end of our study period exhibited a nearly fourfold increase in blood glucose concentration compared with control rats (diabetic, 21.9 ± 0.7 mmol/l, n = 30; control, 5.5 ± 0.3 mmol/l, n = 26; p < 0.05) which was correlated with a significant decrease in immunoreactive serum insulin levels (diabetic, 0.3 ± 0.01 ng/ml; control, 2.0 ± 0.02 ng/ml; p<0.05) as measured by a commercial kit (Alpo Diagnostics, Uppsala, Sweden). As in our previous study (49) body weight in the diabetic group (269.9 ± 3.0 g) was significantly less than control (293.4 ± 2.9 g; p<0.05). With this duration of diabetic conditions, heart weight to body weight ratio remains essentially unchanged from control (49) .
Four to five weeks after STZ or vehicle injection, rats were given an overdose of pentobarbital sodium (150 mg/kg, i.p.) and single ventricular myocytes were dissociated from excised, perfused hearts by a collagenase digestion protocol described previously (27, 35, 49, 50) . The atria were discarded after the digestion procedure and the dissociated myocytes from all regions of ventricle were suspended in Dulbecco's modified Eagle's medium and incubated at 37 o C until used, usually within 6 h of isolation. In some experiments, myocytes were maintained in culture for up to 24 h. For studies of intracellular GSH and Ca 2+ transients, isolated myocytes were first seeded on laminin-coated glass coverslips.
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Measurement of intracellular GSH
Intracellular [GSH] was measured by fluorescence microscopy using the probe monochlorobimane (mBCl, Molecular Probes; Eugene, OR) as described previously (27) . Briefly, glass coverslips with attached myocytes were transferred to a culture dish filled with a loading solution containing (in mmol/l): 138 NaCl, 4.0 KCl, 1.2 MgCl 2 , 1.8 CaCl 2 , 18 glucose, 5 HEPES, and 0.4 mBCl. This solution also contained 2 mmol/l probenecid to inhibit transporter-mediated export of the GSH-bimane adduct. Cells were loaded with mBCl for 50-60 min at room temperature and then transferred to a recording chamber mounted on the stage of an inverted microscope (Nikon Diaphot; Melville, NY). After washout of extracellular probe, myocytes were illuminated with light at 360 nm by means of a Deltascan monochromator system (Photon Technology International; Lawrenceville, NJ). A 15x15 µm optical sampling window was positioned over the center of each myocyte and emission fluorescence (460 nm) was collected with a photometer assembly. For all experiments, only Ca 2+ -tolerant, rodshaped myocytes with clear cross striations were chosen for GSH measurement as these empirical criteria are correlated with the functional integrity of isolated myocytes (35,49,50).
[GSH] was calculated from calibration curves generated with graded concentrations of GSH (7.8-1000 µmol/l) plus rat liver glutathione-S-transferase (0.2 U/ml) to generate the fluorescent GSH-bimane adduct (27). Fluorescence data were collected from each myocyte for 30-60 s to verify steady-state conditions. If fluorescence varied by more than 5 % during this recording period, data from that myocyte were excluded from analysis. with an argon-krypton laser (25 mW argon laser, 0.5% intensity, 100X lens). Cells superfused with room temperature external solution were then field stimulated at 0.5Hz (10V, 10ms) and changes in fluorescence intensities were determined. Fluo-3 was excited by light at 488 nm and fluorescence was measured at 8 wavelengths of >515 nm. The rate of increase of fluorescence was determined using linear regression analysis while fluorescence decay was measured as the time to 50% decrease from the peak value (T 50 ).
Enzymes regulating GSH
In a separate group of rats, the activities of glutathione reductase, -glutamylcysteine synthetase and G6PD
were measured in ventricular tissue samples by spectrophotometric methods. Glutathione reductase activity G6PD activity was measured using a commercial kit (OxisResearch; Foster City, CA). Briefly, ventricular tissue samples were homogenized in supplied diluent and centrifuged at 4 o C (6000 g) for 30 min. A 50 Sl aliquot of supernatant was added to a reaction mixture containing NADP, glucose-6-phosphate and 6-9 phosphogluconic acid. The change in absorbance at 340 nm in the presence of both substrates was measured at 37 o C for 5 min. A second aliquot of supernatant was added to a reaction mixture containing NADP plus 6-phosphogluconic acid alone, and absorbance again measured at 340 nm. G6PD activity was calculated by subtracting the rate of change in absorbance with 6-phosphogluconic acid alone from that measured with the combined substrates to eliminate the contribution of 6-phosphogluconate dehydrogenase to total NADPH production, thus yielding a more accurate estimation of rate-limiting G6PD activity. The net change in absorbance was expressed in mU, defined as the enzyme activity producing 1 nmol of NADPH per minute.
Activities for G-glutamylcysteine synthetase, glutathione reductase and G6PD were normalized per mg protein measured by a commercial kit (Pierce Biotechnology; Rockford, IL).
Experimental protocols. Statistical analysis
Before measuring intracellular GSH, Ca 
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All results are expressed as a mean ± SEM. Comparisons of two groups were made using a Student=s t-test, whereas more than two groups were compared by analysis of variance. When a significant difference among groups was indicated by the initial analysis, individual paired comparisons were made using a Dunnett's t-test. Differences were considered significant at p<0.05. Figure 1A compares mean data from fluorescence microscopy measurements of [GSH] in ventricular myocytes from control (filled bars) and diabetic rats. In general, mean [GSH] in diabetic rat myocytes was 30-40% less than control (p<0.05) and was unchanged for up to 6 h of culture after cell isolation without any further experimental treatment. Moreover, diabetes-induced GSH depletion was similar throughout the 4-5 wk period of diabetic conditions examined in this study: mean [GSH] in myocytes from diabetic rats studied at 4 and 5 wks was 2.4 ± 0.1 amol/Sm 3 (n=108 myocytes from 9 rats) and 2.3 ± 0.1 amol/Sm 3 (n=122 myocytes from 8 rats), respectively. We also compared the change in [GSH] observed with our fluorescence microscopy technique with measurements of GSH/GSSG in suspensions of isolated myocytes using a standard spectrophotometric assay (45, 50) . These latter analyses showed that GSH/GSSG was significantly decreased in the diabetic group by 33% (1.6 ± 0.08, n=5 hearts) compared with control (2.4 ± 0.1, n=6 hearts; p<0.05), verifying conditions of oxidative stress.
RESULTS
Up-regulation of GSH by insulin and DCA
Since cellular GSH content is determined by the balance of GSH utilization and production, we measured the activities of two major enzymes involved in controlling GSH levels. Panels B and C of Figure 1 compare basal activities of G-glutamylcysteine synthetase and glutathione reductase in ventricular tissue samples from control and diabetic rats. Both panels illustrate that these enzymes were mainly inhibited in the diabetic group compared with control but that the activities were not uniformly decreased throughout the heart. The largest changes were observed in samples from left ventricle, where G-glutamylcysteine synthetase and glutathione reductase were decreased by 52 and 33%, respectively (p<0.05). By comparison, tissue samples from the right ventricle showed the least change. Although mean glutathione reductase activity in the right ventricle of diabetic rats was decreased from control by 31%, this change did not reach statistical significance (p=0.09). In 12 previous studies we found no significant regional variations in [GSH] in control or GSH-depleted myocytes [27] . Thus, in the fluorescence microscopy experiments outlined below we used a mixed population of ventricular myocytes and did not analyze regional differences in the control of [GSH].
As shown above in Figure 1A , the decreased [GSH] in diabetic rat myocytes compared with control was stable under basal culture conditions for up to 6 h. However, Figure 
Pathways regulating GSH
The cellular effectors mediating up-regulation of [GSH] by insulin in diabetic rat myocytes were examined in additional series of experiments using blocking agents that target the GSH system at different sites. We first tested the effects of two structurally distinct inhibitors of G6PD, DHEA (30 Smol/l) and 6-AN (1 mmol/l).
G6PD is the rate-limiting enzyme of the pentose pathway that generates NADPH required by glutathione reductase to convert GSSG to GSH (4,9,36,37,38). As shown in Figure 3A , DHEA and 6-AN each blocked in diabetic rat myocytes suggest that G6PD plays a key role in GSH homeostasis, we assayed tissue samples from septum to determine if this enzyme contributed to GSH depletion under diabetic conditions. However, as shown in Figure 3C , G6PD activity in our diabetic model was not different from control. Finally, we assessed the effects of insulin on the other major GSH-related enzymes. Figure 3D shows that insulin treatment of diabetic rat myocytes significantly increased G-glutamylcysteine synthetase (G-GCS) activity but had no effect on glutathione reductase (GR). In control myocytes, both enzymes were unaffected by insulin (data not shown) as was [GSH] (Fig. 2B) . Likewise, insulin treatment of control cells had no significant effect on GSH/GSSG: insulin-treated, 2.4 ± 0.1, n=5 hearts; untreated, 2.4 ± 0.1, n=6 hearts.
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Insulin regulation of mechanical properties and Ca
2+ transients
The functional impact of diabetes-induced GSH dysregulation was analyzed in relation to changes in mechanical properties and Ca 2+ transients as measured in field stimulated myocytes at room temperature. Our model of diabetes, as in other studies (6) , was marked by significant decreases in myocyte mechanical activity and prolonged kinetics of Ca 2+ transients when compared with controls. Figure 4A shows superimposed length changes in a control and diabetic rat myocyte paced at 0.5 Hz. In addition to a marked decrease in the extent of shortening, the diabetic rat myocyte was characterized by profound decreases in the rate of shortening and relengthening compared with control. These changes in mechanical properties correlated closely with alterations in evoked Ca Table 1 which also shows the effect of insulin treatment. In our contraction studies, insulin treatment of diabetic rat myocytes for 3-4 h normalized the rates of cell shortening (-dL/dt) and re-lengthening (+dL/dt), and percent shortening, whereas these parameters were unaffected by insulin in control myocytes. Similar to regulation of GSH (Fig. 3B) , the effect of insulin on mechanical parameters in diabetic rat myocytes was blocked by pre-treating cells with DHEA plus BSO. Insulin also normalized kinetic parameters and peak Ca Figure 5A shows concentration-response data for GSH (filled circles) and NAC on mechanical properties (-dL/dt, +dL/dt, % shortening ) of diabetic rat myocytes. The changes in mechanical properties elicited by GSH and NAC were similar over the concentration range of 0.1 to 10 mmol/l but significance only occurred at 10 mmol/l, which was the test concentration used in all subsequent experiments. Figure 5B shows that in contrast to diabetic rat myocytes, neither 10 mmol/l GSH nor NAC significantly affected mechanical parameters in control myocytes. Although these exogenous reductants significantly improved mechanical function in diabetic rat myocytes, they did not normalize all measured parameters. Specifically, in diabetic rat myocytes treated with GSH -dL/dt (139.8 ± 9.4 Sm/s) and percent shortening (10.8 ± 0.3%) were significantly less than in comparably treated control myocytes (201.5 ± 27.6
Sm/s and 12.3 ± 0.5%, respectively; p<0.05). +dL/dt in GSH-treated diabetic cells was also less than control (143.0 ± 10.2 vs 169.8 ± 17.3 Sm/s), but this difference was not significant (p=0.16). Similar differences in mechanical properties were also observed in NAC-treated diabetic and control myocytes (data not shown).
Parallel confocal experiments were conducted to assess the effects of GSH and NAC on Ca transients. Figure 6A shows that GSH and NAC treatment of diabetic rat myocytes increased the rate of Ca (Fig. 6B) . However, in contrast to the effects on mechanical properties (Fig. 5 ), GSH and NAC both normalized parameters of the Ca 
DISCUSSION
Oxidative stress and GSH in diabetic heart
Intracellular GSH is an essential tripeptide that directly or indirectly regulates a number of biological processes, such as antioxidant defenses, DNA synthesis, ion transport, enzyme activity, transcription, and signal transduction (9,37,38). Much of the control of these processes by GSH is mediated by its regulation of the redox state of protein thiol (-SH) groups of cysteine residues, which determine the structure and activity of many proteins required for normal cell activity (36). Under oxidative stress conditions, free thiols can undergo a number of different modifications to yield unique chemical intermediates that can lead to a gain or loss of protein function. GSH has been shown to control the biological activity of proteins by preventing modification of thiols through detoxification of reactive oxygen species or by directly participating in the reduction of thiol intermediates (36). Consequently, maintenance of an adequate [GSH] is important for protecting protein thiol groups from oxidative modification. This is accomplished in mammalian cells through the activities of glutathione reductase, which converts GSSG to GSH using NADPH as a source of reducing equivalents, and G-glutamylcysteine synthetase, the rate-limiting step in de novo GSH synthesis (9, 20, 36, 37, 38) .
Human and animal studies show that cardiovascular complications associated with diabetes are linked to oxidative stress (8, 12 ) that causes profound and dynamic changes in GSH status. For example, some studies have reported an increase in cardiac GSH content, suggesting that compensatory up-regulation of GSH-related pathways occurs in response to oxidative conditions (46, 51) . In agreement with this hypothesis, the activity of glutathione reductase has been shown to be increased in some studies (46, 51) . However, GSH depletion is observed in most diabetic models, which is most likely a function of the duration of diabetic conditions or the severity of hyperglycemia (11, 50) . This change in redox status reflects not only an increased GSH demand for antioxidant and conjugation reactions but also a decreased supply of GSH. In particular, our present study and others (11, 31) show that the activities of -glutamylcysteine synthetase and glutathione reductase are decreased in the diabetic heart compared with control (Figs. 1B and 1C) . The loss of function of these key enzymes results in decreased rates of GSH synthesis and decreased regeneration of GSH from GSSG.
Glucose metabolism and GSH
Although glutathione reductase and -glutamylcysteine synthetase are generally considered major enzymes involved in GSH homeostasis, up-stream accessory pathways such as G6PD and pyruvate dehydrogenase have also been shown to be key factors affecting [GSH] . G6PD is the rate-limiting enzyme of the cytosolic pentose pathway that generates NADPH utilized by glutathione reductase (9, 36, 37, 38) . Recent data show that targeted deficiency of G6PD in mice leads to GSH depletion, accumulation of GSSG, and impaired Ca 2+ handling in ventricular myocytes (24). In experimental models of diabetes, variable changes in the activity of this enzyme have been reported (23,51), and in our study we found no change in basal G6PD activity in diabetic hearts compared with control (Fig. 3C) . Nevertheless, this enzyme played a key role in insulin-mediated normalization of [GSH] , as evidenced by inhibitory effects of DHEA and 6-AN (Fig. 3A) . Residualglutamylcysteine synthetase activity also contributed to GSH up-regulation by insulin in diabetic rat myocytes, such that when this enzyme was inhibited along with G6PD, insulin had no effect (Fig. 3B) . Together, these findings indicate that an essential function of glucose metabolism in the heart, independent of ATP production, is the regulation of GSH levels for redox control of cell function.
In contrast to variable changes in G6PD, there is general agreement that the activity of pyruvate dehydrogenase is decreased in diabetic rat heart due to an increased state of phosphorylation mediated by pyruvate dehydrogenase kinase (19) . DCA inhibits pyruvate dehydrogenase kinase thereby stimulating overall pyruvate dehydrogenase activity and promoting glucose and pyruvate oxidation (1, 42) . Moreover, DCA increases the supply of substrate for active pyruvate dehydrogenase by a concomitant increase in glucose and 18 pyruvate uptake (30). In the present study we found that DCA rapidly increased [GSH] to control levels in diabetic rat myocytes but that this effect was transient ( Fig. 2A) . Although we did not examine the mechanism for the decline in [GSH] with prolonged DCA exposure, which was also observed in control myocytes, previous studies suggest that this response may be due to glutathione-S-transferase-catalyzed conjugation of intracellular DCA with GSH (21), which would be expected to cause GSH depletion.
Despite evidence of its influence on GSH, the link between pyruvate dehydrogenase and GSH homeostasis is not fully understood. Experiments in isolated rat hearts suggest that increased pyruvate dehydrogenase activity leads to citrate accumulation that increases NADPH production by cytosolic isocitrate dehydrogenase or inhibits of phosphofructokinase thereby diverting glycolytic flux to NADPH-generating G6PD (42).
Compared to DCA, insulin in our experiments produced a delayed but more sustained increase in [GSH] over a 6 h incubation period (Fig. 2A) . The reason for the lag in response to insulin may simply be due to a dose effect; i.e. a higher insulin concentration would elicit a more rapid response. However, Lloyd et al. (30) report that insulin and DCA exert quantitatively different effects on substrate oxidation in isolated rat heart. In particular, they show that DCA exerts a more robust stimulation of pyruvate oxidation than insulin. This may be due to different mechanisms controlling the phosphorylation state of pyruvate dehydrogenase; i.e. DCA inhibits pyruvate dehydrogenase kinase (1,42) whereas insulin increases pyruvate dehydrogenase phosphatase activity (29,30). Alternatively, the different time course of GSH up-regulation may be related to the more diverse metabolic effects of insulin on the myocardium compared with DCA, such as increased expression or activity of hexokinase (33) or -glutamylcysteine synthetase (20; Fig. 3D ). Currently there is no compelling evidence that glutathione reductase is directly regulated by insulin (44) despite the fact that this enzyme is essential for GSH homeostasis. Indeed, our study found no significant change in glutathione reductase activity in the presence of insulin (Fig. 3D) . Cellular functions of GSH GSH is a key molecule that regulates a multitude of redox-sensitive, physiological processes (9,37,38) through thiol-disulfide exchange reactions that directly involve GSH or that are catalyzed by the oxidoreductase glutaredoxin, which requires GSH as cofactor (15) . Recent data suggest that GSH and glutaredoxin are important regulators of pathophysiological signals activated by oxidative stress, such as apoptosis (7, 22) . We also found evidence of regulation of myocyte Ca 2+ handling and mechanical properties by GSH in the present experiments (Figs. 5 and 6 ). Our findings are consistent with studies of G6PD deficiency in non-diabetic myocytes (24) which show similar degrees of GSH depletion and mechanical dysfunction as in our diabetic model. However, it is not known whether regulation of myocyte Ca 2+ handling is mediated by the antioxidant or reducing properties of GSH. In the former case, GSH may protect Ca 2+ handling proteins from oxidation by directly scavenging reactive oxygen species or by acting as cofactor for inactivation of hydroperoxides by glutathione peroxidase (10, 48) . Alternatively, GSH may directly reduce oxidized protein thiols or participate as a cofactor for glutaredoxin-catalyzed thiol reduction (15) . The same possible mechanisms also apply to NAC, which increases [GSH] in depleted myocytes (28) and which showed similar effects as GSH in the present study ( Fig. 5 and 6 ). Additional investigation is necessary to better define the antioxidant and reducing effects of exogenous reductants.
It is clear that diabetes elicits significant contractile dysfunction in cardiomyocytes that is accompanied by Table 1 and are shown for purposes of comparison. Table 1 and are shown for purposes of comparison. Myocytes were pre-treated with 100 nmol/l insulin for 3-4 h. -dL/dt, maximum rate of myocyte shortening; +dL/dt, maximum rate of relengthening; DHEA, dehydroepiandrosterone; BSO, buthionine sulfoximine; f.a.u., fluorescence intensity in arbitrary units measured as (F max -F 0 )/F 0 . Mean data for mechanical studies based on 20-28 control myocytes and 26-35 diabetic rat myocytes. Mean data for Ca 2+ transients based on 37 untreated and 32 insulin-treated myocytes in the control group and 32 untreated and 27 insulin-treated myocytes from the diabetic group. * = p<0.05 compared with untreated control. 
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TABLES
Control
